


\$78 MILLION IN 2025

PAN-MASS CHALLENGE IMPACT

The Pan-Mass Challenge raises funds for Dana-Farber Cancer Institute and the Jimmy Fund's lifesaving mission to conquer cancer. In 2025, committed riders, donors, sponsors, and volunteers joined together to contribute \$78 million, which is 68% of the Jimmy Fund's annual revenue.

This chart depicts rider-designated and unrestricted funds raised, and shows how Dana-Farber allocates them to bring us Closer By the Mile.



* Including Cutaneous Oncology, Head and Neck Oncology, Joint Ventures, and Imaging

2025 PMC Gift Chart Detail

*Below are categories within the chart depicting the **\$78 million** gift from the Pan-Mass Challenge in 2025, along with short descriptive paragraphs explaining each item.*

Hematologic Oncology, \$11.8M

Dana-Farber’s Center for Hematologic Oncology is answering key questions about and improving treatments for all types of blood cancers including leukemia, lymphoma, multiple myeloma, and Waldenström’s macroglobulinemia, as well as related disorders of the blood, such as aplastic anemia and myelodysplasia. The Center also includes the Institute’s Stem Cell Transplantation Program, which was established in 1972 and is one of the largest and most experienced in the world. The Center continues to expand its scientific and clinical capabilities in order to pursue promising research opportunities and accommodate increased patient volume.

Pediatric Oncology, \$10.6M

The Department of Pediatric Oncology at Dana-Farber is advancing research and care to improve outcomes for young patients with cancer. Department faculty are spearheading studies to reveal the biological drivers of pediatric brain cancers, solid tumors, and hematologic malignancies; identifying patients who are at risk for disease progression or relapse; and leading efforts to improve pediatric cancer care in countries around the world—all while addressing the full range of patient and family needs. This comprehensive excellence in the lab and clinic led to Dana-Farber/Boston Children’s Cancer and Blood Disorders Center being named top ranked pediatric cancer program in New England and #3 in the nation in *US News & World Report’s* 2025-26 “Best Children’s Hospitals” list. Dana-Farber/Boston Children’s has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking’s inception in 2007, earning more #1 rankings than any other program.

Adult Oncology, \$9.8M

Driven by a balanced commitment to scientific and clinical excellence that is unique among cancer centers, Dana-Farber is pioneering novel detection, prevention, and treatment strategies while delivering comprehensive and compassionate care. The Institute continually earns recognition for leadership in cancer research and treatment, having been

2025 PMC Gift Chart Detail

the top ranked cancer hospital in New England by *U.S. News & World Report* for 25 consecutive years, and the only cancer center ranked in the top 3 nationally for both adult and pediatric cancer programs.

Gastrointestinal Oncology, \$6.1M

The Center for Gastrointestinal Oncology at Dana-Farber is dedicated to the study and treatment of all types of gastrointestinal cancer, including colorectal, esophageal, neuroendocrine, pancreatic, stomach, and liver cancers. In addition to providing personalized patient care, the Center's multidisciplinary team of experts is advancing an ambitious research platform to uncover the biological underpinnings of tumors, identify new genetic targets, and examine lifestyle factors associated with disease progression.

Cancer Biology, \$5.9M

Dana-Farber's Department of Cancer Biology studies fundamental problems in biology that affect cancer to translate laboratory findings into more effective treatments. Researchers are driving early-stage drug discovery and testing; studying the genetics of brain development; and advancing breakthrough investigations in energy and homeostasis, structural biology, systems biology, and women's cancers.

Data Science, \$4.8M

Dana-Farber's Department of Data Science leverages the latest knowledge and tools from computational science to propel cancer research and provides investigators with access to expert quantitative scientists. The department is a world leader in the design and implementation of innovative preclinical and clinical trials, analysis of patient genomic data, development of strategies to overcome drug resistance, and the training of biostatisticians and computational biologists, among other activities.

Longwood Center: State-of-the-Art Research Labs, \$4.3M

Opened in 2015, the Longwood Center is a hub of creative, collaborative, and cutting-edge science that houses the Institute's robust cancer biology, chemical biology, and drug

2025 PMC Gift Chart Detail

development programs. Leveraging this state-of-the-art facility and sophisticated technologies, investigators are propelling groundbreaking research to accelerate the discovery and delivery of potentially lifesaving therapies to patients.

Radiation Oncology, \$3.7M

The Institute's Department of Radiation Oncology provides individualized radiation treatment for patients with breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, head and neck cancers, sarcomas, thoracic cancer, lymphoma, and cancers of the central nervous system. The department also advances basic and clinical research to enhance diagnostic approaches and develop more precise radiation therapies.

Population Sciences, \$3.3M

The McGraw/Patterson Center for Population Sciences at Dana-Farber is advancing an expansive and diversified research portfolio to identify and mitigate cancer risk in individuals and communities, reduce healthcare disparities, improve care delivery, and enhance early detection and prevention. Key projects include the development of new technologies to help patients better communicate with health care providers, cancer prevention outreach campaigns tailored to at-risk populations, and analyses of genetic factors and vulnerabilities of certain forms of cancer.

Neuro-Oncology, \$2.7M

Dana-Farber's Center for Neuro-Oncology mobilizes interdisciplinary teams of experts to provide individualized care for patients with tumors of the brain or spinal cord, as well as for neurologic complications of cancer and its treatments. Center investigators are developing novel targeted drugs, immunotherapies, and combination approaches for treating a range of common and rare neurologic malignancies. Patients also have access to a broad spectrum of clinical trials of next-generation therapies.

Oncologic Pathology, \$2.5M

The Department of Oncologic Pathology provides pathology resources for investigators

2025 PMC Gift Chart Detail

across Dana-Farber, supports the advancement of precision medicine and immunotherapy, and develops preclinical models for cancer studies

Nursing and Patient Care, \$2.2M

The Department of Nursing and Patient Care Services at Dana-Farber mobilizes highly skilled nurses who provide clinical expertise, emotional support, and patient-centered care. Additionally, nurse-scientists are improving communication between patients and doctors, reducing healthcare disparities, and developing evidence-based interventions to manage cancer symptoms. In recognition of its nursing excellence, Dana-Farber has received the prestigious Magnet® designation from the American Nurses Credentialing Center five consecutive times—an honor realized by just eight percent of all hospitals nationwide.

Cancer Immunology and Virology, \$2M

Dana-Farber's Department of Cancer Immunology and Virology conducts basic research and develops new therapeutic strategies based on novel insights. Driven by a commitment to interdisciplinary collaboration, investigators are uncovering the complex underpinnings of the immune system, analyzing the human immunodeficiency virus (HIV), and piloting new vaccines and immunotherapies.

Women's Cancers, \$1.9M

Dana-Farber's Susan F. Smith Center for Women's Cancers bridges compassionate care with world-class basic and clinical research. Susan F. Smith Center faculty are making strides against breast and gynecologic cancers by expanding the use of immunotherapy, developing targeted and combination treatments, analyzing disease risk, conducting prevention studies, and advancing new strategies for combating drug-resistant and metastatic tumors.

Thoracic Oncology, \$1.4M

Dana-Farber's Carole M. and Philip L. Lowe Center for Thoracic Oncology utilizes multidisciplinary care teams of medical and radiation oncologists, surgeons, pulmonologists, and pathologists to treat lung cancers—including non-small cell lung cancer, small cell lung

2025 PMC Gift Chart Detail

cancer, and mesothelioma—as well as other cancers of organs within the chest. In addition, physician-scientists at the Lowe Center are refining existing therapies and finding new treatment approaches using genomic data, novel chemical biology tools, advanced technologies, and immunotherapies.

Genitourinary Oncology, \$1.3M

The Lank Center for Genitourinary Oncology at Dana-Farber provides compassionate care and the most effective therapies for prostate, kidney, bladder, and testicular cancer, among other related malignancies. Lank Center researchers are pioneering novel detection and prevention strategies, gleaned critical biological insights to develop new therapies, and speeding the delivery of new targeted, combination, and immune-based treatments to patients.

Psychosocial Oncology and Palliative Care, \$1.3M

The Department of Supportive Oncology at Dana-Farber aims to alleviate the burden of cancer and improve quality of life for patients and families by providing one-on-one consultations, support groups, and other personalized services. An integrated team of specially trained physicians, nurses, pharmacists, psychologists, and social workers delivers joint care and supports each patient's unique needs from diagnosis through treatment and into survivorship.

Sarcoma and Bone Cancers, \$1M

Dana-Farber's Center for Sarcoma and Bone Oncology is a world leader in studying, diagnosing, and treating these diverse and complex tumors. Researchers are revealing invaluable information about tumor biology, identifying the genetic mechanisms of disease progression, redefining sarcoma subtypes, and rapidly translating the latest discoveries into clinical trials to test novel therapies.

Other Designations, \$0.9M

PMC support is allocated to areas across Dana-Farber. Among them includes the Center for Cutaneous Oncology, dedicated to providing comprehensive care for patients with skin

2025 PMC Gift Chart Detail

cancer; the Head and Neck Cancer Treatment Center, dedicated to treating patients with cancers including throat, larynx, nose, sinuses, and mouth; and the Department of Imaging, providing dedicated cancer imaging services and conducting transformative imaging research enabling breakthrough discoveries in cancer through the use of imaging.

Precision Cancer Medicine, \$0.5M

Dana-Farber is a world leader in precision cancer medicine—a growing field in which researchers are uncovering new information about the genetic makeup of cancer to find more effective treatments. Through *Profile*, the Institute’s flagship precision medicine initiative, every patient who comes to Dana-Farber has the opportunity for their tumor to be analyzed for known cancer-promoting genetic mutations. Clinically relevant information from the test can be shared with doctors to help guide treatment. More than 70,000 patient tumors have been analyzed since *Profile*’s inception in 2011, making it one of the largest and most comprehensive patient-based genomic projects in the world.